{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:58:27Z","timestamp":1780433907855,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.steroids.2016.06.002","type":"journal-article","created":{"date-parts":[[2016,8,7]],"date-time":"2016-08-07T11:55:35Z","timestamp":1470570935000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of A and B rings. Facile synthesis and inhibition of CYP17A1 catalytic activity"],"prefix":"10.1016","volume":"115","author":[{"given":"Vladimir A.","family":"Kostin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir A.","family":"Zolottsev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Kuzikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami A.","family":"Masamrekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria V.","family":"Shumyantseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Veselovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey V.","family":"Stulov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir P.","family":"Timofeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Y.","family":"Misharin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2016.06.002_b0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1381612805666230109214333","article-title":"Inhibitors of 17a-hydroxylase\/17,20-lyase (CYP17) potential agents for the treatment of prostate cancer","volume":"5","author":"Njar","year":"1999","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.steroids.2016.06.002_b0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/1521-4184(200204)335:4<119::AID-ARDP119>3.0.CO;2-#","article-title":"Inhibition of CYP17, a new strategy for the treatment of prostate cancer","volume":"4","author":"Hartmann","year":"2002","journal-title":"Arch. Pharm. Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0015","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.bmc.2007.05.046","article-title":"Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development","volume":"15","author":"Bruno","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/157489207779561453","article-title":"Inhibitors of steroidal cytochrome P450 enzymes as targets for drug development","volume":"2","author":"Baston","year":"2007","journal-title":"Recent Pat. Anticancer Drug Discovery"},{"key":"10.1016\/j.steroids.2016.06.002_b0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/dmd.109.031351","article-title":"Targeting of drug-metabolizing enzymes for effective chemoprevention and chemotherapy","volume":"38","author":"Swanson","year":"2010","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.steroids.2016.06.002_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/era.11.196","article-title":"Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer","volume":"12","author":"Bedoya","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.steroids.2016.06.002_b0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.steroids.2014.12.021","article-title":"CYP17A1 inhibitors in castration-resistant prostate cancer","volume":"95","author":"Gomez","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PPO.0b013e31827e0b6f","article-title":"Agents that target androgen synthesis in prostate cancer","volume":"19","author":"Feraldeschi","year":"2013","journal-title":"Cancer J."},{"key":"10.1016\/j.steroids.2016.06.002_b0045","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/jm501239f","article-title":"Discovery and development of Galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer","volume":"58","author":"Njar","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2014.01.013","article-title":"A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone","volume":"143","author":"Garrido","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"7560","key":"10.1016\/j.steroids.2016.06.002_b0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2016.06.002_b0060","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/jm400048v","article-title":"Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer","volume":"56","author":"Purushottamachar","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.steroids.2006.10.002","article-title":"Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives","volume":"72","author":"Ga\u0161i","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.steroids.2007.09.005","article-title":"Synthesis of some epoxy and\/or N-oxy 17-picolyl and 17-picolinylidene-androst-5-ene derivatives and evaluation of their biological activity","volume":"73","author":"Djurendi\u0107","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0075","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ejmech.2012.06.030","article-title":"Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives","volume":"54","author":"Djurendi\u0107","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0080","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1016\/j.bmc.2013.09.063","article-title":"17(E)-Picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies","volume":"21","author":"Ajdukovi\u0107","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1556\/ABiol.66.2015.1.4","article-title":"Determination of 17\u03b1-hydroxylase-C17,20-lyase (P45017\u03b1) enzyme activities and their inhibition by selected steroidal picolyl and picolinylidene compounds","volume":"66","author":"Szab\u00f3","year":"2015","journal-title":"Acta Biol. Hung."},{"key":"10.1016\/j.steroids.2016.06.002_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.steroids.2011.10.007","article-title":"Synthesis of 21-nitrogen substituted pregna-5,17(20)-dienes from pregnenolone","volume":"77","author":"Stulov","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.steroids.2014.06.014","article-title":"Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17a-hydroxylase\/17,20-lyase (CYP17A1) inhibitors","volume":"88","author":"Kuzikov","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0100","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jinorgbio.2005.01.014","article-title":"Electrochemical reduction of cytochrome P450 as an approach to the construction of biosensors and bioreactors","volume":"99","author":"Shumyantseva","year":"2005","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.steroids.2016.06.002_b0105","first-page":"55","article-title":"Screening of potential substrates or inhibitors of cytochrome P450 17A1 (CYP17A1) by electrochemical methods","volume":"5","author":"Shumyantseva","year":"2011","journal-title":"Biochem. (Moscow) Ser. B Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0110","first-page":"176","volume":"vol. 2","author":"Oliveto","year":"1972"},{"key":"10.1016\/j.steroids.2016.06.002_b0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/00397917708050738","article-title":"Synthesis of Pregn-17\/20\/-en-21-oic acid derivatives. The Wittig-Horner reaction on steroidal 17-ketones","volume":"7","author":"Wicha","year":"1977","journal-title":"Synth. Commun."},{"key":"10.1016\/j.steroids.2016.06.002_b0120","series-title":"Reagents for Organic Synthesis","author":"Fieser","year":"1968"},{"key":"10.1016\/j.steroids.2016.06.002_b0125","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/jo01319a009","article-title":"Hydroxylation of alpha, beta.-unsaturated nitriles and esters in steroid systems","volume":"44","author":"Freerksen","year":"1979","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0130","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF00566078","article-title":"Preparation of 21-aldehydes of 17(20)-steroids","volume":"15","author":"Popova","year":"1979","journal-title":"Chem. Nat. Compd."},{"issue":"7383","key":"10.1016\/j.steroids.2016.06.002_b0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature10743","article-title":"Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001","volume":"482","author":"DeVore","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2016.06.002_b0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1261\/rna.1563609","article-title":"DOCK 6: combining techniques to model RNA-small molecule complexes","volume":"15","author":"Lang","year":"2009","journal-title":"RNA"},{"key":"10.1016\/j.steroids.2016.06.002_b0145","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1016\/S0040-4039(01)93017-5","article-title":"A simple synthesis of 2-oxazolines, 2-oxazines, 2-thiazolines and 2-imidazolines","volume":"45","author":"Vorbr\u0171ggen","year":"1981","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.steroids.2016.06.002_b0150","doi-asserted-by":"crossref","first-page":"9353","DOI":"10.1016\/0040-4020(93)80021-K","article-title":"A simple synthesis of 2-oxazolines, 2-oxazines, 2-thiazolines and 2-substituted benzoxazoles","volume":"49","author":"Vorbr\u0171ggen","year":"1993","journal-title":"Tetrahedron"},{"key":"10.1016\/j.steroids.2016.06.002_b0155","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0039-128X(94)90058-2","article-title":"Synthesis of new brassinosteroids with potential activity as antiecdysteroids","volume":"59","author":"Brosa","year":"1994","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0160","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0039-128X(02)00004-1","article-title":"Synthesis of [26-2H3]brassinosteroids","volume":"67","author":"Khripach","year":"2002","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.steroids.2011.10.009","article-title":"Brassinosteroids and analogs as neuroprotectors: synthesis and structure-activity relationships","volume":"77","author":"Ismaili","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2016.06.002_b0170","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bmc.2007.10.056","article-title":"Synthesis and cytotoxicity evaluation of 22,23-oxygenated stigmastane derivatives","volume":"16","author":"Misharin","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0175","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbapap.2010.07.008","article-title":"Electrochemical investigations of cytochrome P450","volume":"1814","author":"Shumyantseva","year":"2011","journal-title":"Biochim. Biophys. Acta Proteins Proteomics"},{"key":"10.1016\/j.steroids.2016.06.002_b0180","series-title":"Electrochemical Methods. Fundamental and Applications","author":"Bard","year":"2001"},{"key":"10.1016\/j.steroids.2016.06.002_b0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-0728(79)80075-3","article-title":"General expression of the linear potential sweep voltammogram in the case of diffusionless electrochemical systems","volume":"101","author":"Laviron","year":"1979","journal-title":"J. Electroanal. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b0190","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1021\/ac50058a010","article-title":"Rotating ring-disk enzyme electrode for biocatalysis kinetic studies and characterization of the immobilized enzyme layer","volume":"52","author":"Kamin","year":"1980","journal-title":"Anal. Chem."},{"key":"10.1016\/j.steroids.2016.06.002_b9000","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsbmb.2012.10.019","article-title":"Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition","volume":"134","author":"Krug","year":"2013","journal-title":"J. Steroid Biochem. Molec. Biol."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X1630068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X1630068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:54:47Z","timestamp":1749052487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X1630068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":39,"alternative-id":["S0039128X1630068X"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2016.06.002","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of A and B rings. Facile synthesis and inhibition of CYP17A1 catalytic activity","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2016.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}